JP2007535471A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007535471A5 JP2007535471A5 JP2006509122A JP2006509122A JP2007535471A5 JP 2007535471 A5 JP2007535471 A5 JP 2007535471A5 JP 2006509122 A JP2006509122 A JP 2006509122A JP 2006509122 A JP2006509122 A JP 2006509122A JP 2007535471 A5 JP2007535471 A5 JP 2007535471A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- binds
- library
- cll
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/379,151 US7435412B2 (en) | 2000-12-08 | 2003-03-04 | Chronic lymphocytic leukemia cell line |
| US10/379,151 | 2003-03-04 | ||
| US10/736,188 US20040198661A1 (en) | 2000-12-08 | 2003-12-15 | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US10/736,188 | 2003-12-15 | ||
| PCT/US2004/006577 WO2004078938A2 (en) | 2003-03-04 | 2004-03-04 | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007535471A JP2007535471A (ja) | 2007-12-06 |
| JP2007535471A5 true JP2007535471A5 (https=) | 2008-01-24 |
Family
ID=32965320
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006509122A Pending JP2007535471A (ja) | 2003-03-04 | 2004-03-04 | 慢性リンパ性白血病細胞由来のポリペプチド及び抗体並びにそれらの関連する適用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20040198661A1 (https=) |
| EP (1) | EP1606388A4 (https=) |
| JP (1) | JP2007535471A (https=) |
| KR (1) | KR20050108381A (https=) |
| CA (1) | CA2517968A1 (https=) |
| WO (1) | WO2004078938A2 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7408041B2 (en) | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US9249229B2 (en) * | 2000-12-08 | 2016-02-02 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| CA2436595C (en) * | 2000-12-08 | 2011-11-08 | Alexion Pharmaceuticals, Inc. | Chronic lymphocytic leukemia cell line and its use for producing an antibody |
| US20060057651A1 (en) * | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| CA2462883A1 (en) * | 2001-10-12 | 2003-04-17 | Schering Corporation | Use of bispecific antibodies to regulate immune responses |
| AU2012211347B9 (en) * | 2004-07-20 | 2015-06-18 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| SG10201400426XA (en) | 2006-01-12 | 2014-07-30 | Alexion Pharma Inc | Antibodies to ox-2/cd200 and uses thereof |
| WO2008089022A2 (en) * | 2007-01-11 | 2008-07-24 | Boehringer Ingelheim International Gmbh | Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts |
| US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| DK2164514T3 (en) | 2007-05-21 | 2017-02-27 | Alderbio Holdings Llc | Antibodies to IL-6 and its use |
| US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| AU2008279618B2 (en) * | 2007-07-25 | 2014-05-22 | Alexion Pharmaceuticals, Inc. | Methods and compositions for treating autoimmune disease |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| KR20110112307A (ko) * | 2008-11-25 | 2011-10-12 | 앨더 바이오파마슈티컬즈, 인코포레이티드 | 알부민을 상승시키고 및／또는 ｃｒｐ를 낮추는 ｉｌ６의 길항제 |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP2477658A2 (en) * | 2009-09-16 | 2012-07-25 | Duke University | Hiv-1 antibodies |
| CN102740888B (zh) | 2009-11-24 | 2016-10-12 | 奥尔德生物制药公司 | Il-6抗体及其用途 |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| SG182408A1 (en) | 2010-01-11 | 2012-08-30 | Alexion Pharma Inc | Biomarkers of immunomodulatory effects in humans treated with anti-cd200 antibodies |
| KR20130036192A (ko) | 2010-02-11 | 2013-04-11 | 알렉시온 파마슈티칼스, 인코포레이티드 | 항-ｃｄ200 항체들을 이용한 치료 및 진단 방법 |
| CA2818813C (en) | 2010-11-23 | 2020-10-06 | Alder Biopharmaceuticals, Inc. | Anti-il-6 antibodies for the treatment of oral mucositis |
| WO2012106634A1 (en) | 2011-02-03 | 2012-08-09 | Alexion Pharmaceuticals, Inc. | Use of an anti-cd200 antibody for prolonging the survival of allografts |
| EP2723380B1 (en) | 2011-06-24 | 2019-08-21 | Stephen D. Gillies | Light chain immunoglobulin fusion proteins and methods of use thereof |
| RU2769282C2 (ru) | 2016-06-20 | 2022-03-30 | Кимаб Лимитед | Анти-PD-L1 и IL-2 цитокины |
| US11761963B2 (en) | 2017-09-27 | 2023-09-19 | Alexion Pharmaceuticals, Inc. | Biomarker signature for predicting tumor response to anti-CD200 therapy |
| WO2019126536A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals Inc. | Humanized anti-cd200 antibodies and uses thereof |
| WO2019126133A1 (en) | 2017-12-20 | 2019-06-27 | Alexion Pharmaceuticals, Inc. | Liquid formulations of anti-cd200 antibodies |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3940475A (en) * | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
| US4289747A (en) * | 1978-12-26 | 1981-09-15 | E-Y Laboratories, Inc. | Immunological determination using lectin |
| US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5780279A (en) * | 1990-12-03 | 1998-07-14 | Genentech, Inc. | Method of selection of proteolytic cleavage sites by directed evolution and phagemid display |
| CA2095633C (en) * | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| CA2580812A1 (en) * | 1991-06-27 | 1993-01-07 | Bristol-Myers Squibb Company | Ctla4 receptor, fusion proteins containing it and uses thereof |
| US5508717A (en) * | 1992-07-28 | 1996-04-16 | Sony Corporation | Computer pointing device with dynamic sensitivity |
| EP0892643B2 (en) * | 1996-03-20 | 2009-09-02 | Bristol-Myers Squibb Company | Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith |
| US6011138A (en) * | 1997-02-20 | 2000-01-04 | Idec Pharmaceuticals Corporation | Gamma-1 anti-human CD23 monoclonal antibodies |
| US6955811B2 (en) * | 1997-11-07 | 2005-10-18 | Trillium Therapeutics Inc. | Methods of inhibiting immune response suppression by administering antibodies to OX-2 |
| US7223729B2 (en) * | 1997-11-07 | 2007-05-29 | Trillium Therapeutics Inc. | Methods of treating allergy by administering a CD200 protein |
| EP1032662B1 (en) * | 1997-11-07 | 2006-03-08 | Trillium Therapeutics Inc. | Methods and compositions for immunomodulation |
| US20020192215A1 (en) * | 1999-04-13 | 2002-12-19 | Schering Corporation, A New Jersey Corporation | Novel uses of mammalian OX2 protein and related reagents |
| WO2001068697A2 (en) * | 2000-03-17 | 2001-09-20 | Gorczynski Reginald M | Methods and compositions for immunoregulation |
| US7306801B2 (en) * | 2000-05-15 | 2007-12-11 | Health Research, Inc. | Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein |
| CA2417874C (en) * | 2000-08-03 | 2012-10-02 | Transplantation Technologies Inc. | Use of ox-2 inhibitors for the treatment of cancer |
| US20030017491A1 (en) * | 2000-09-14 | 2003-01-23 | Zuo-Rong Shi | Chromogenic in situ hybridization methods, kits, and compositions |
| ATE406385T1 (de) * | 2000-11-22 | 2008-09-15 | Trillium Therapeutics Inc | Verkürztes cd200 |
| CA2436595C (en) * | 2000-12-08 | 2011-11-08 | Alexion Pharmaceuticals, Inc. | Chronic lymphocytic leukemia cell line and its use for producing an antibody |
| US7408041B2 (en) * | 2000-12-08 | 2008-08-05 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US6953417B2 (en) * | 2003-11-17 | 2005-10-11 | Borgwarner Inc. | Method for controlling a dual clutch transmission |
| JP2007518827A (ja) * | 2004-02-02 | 2007-07-12 | シェーリング コーポレイション | Ｃｄ２００およびｃｄ２００ｒを調節する方法 |
-
2003
- 2003-12-15 US US10/736,188 patent/US20040198661A1/en not_active Abandoned
-
2004
- 2004-03-04 EP EP04717403A patent/EP1606388A4/en active Pending
- 2004-03-04 CA CA002517968A patent/CA2517968A1/en not_active Abandoned
- 2004-03-04 WO PCT/US2004/006577 patent/WO2004078938A2/en not_active Ceased
- 2004-03-04 JP JP2006509122A patent/JP2007535471A/ja active Pending
- 2004-03-04 KR KR1020057016376A patent/KR20050108381A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007535471A5 (https=) | ||
| CN102639564B (zh) | 抗-cmet抗体及其用于癌症的检测和诊断的用途 | |
| JP2019116474A5 (https=) | ||
| JP4280803B2 (ja) | 慢性リンパ性白血病細胞株および抗体を産生するためのその使用 | |
| JP6180931B2 (ja) | 癌の診断および／または予後のための新規な抗体 | |
| JP2009517057A5 (https=) | ||
| CN103827144B (zh) | 新的抗cxcr4抗体及其用于检测和诊断癌症的用途 | |
| JP2013506428A5 (https=) | ||
| JP2012176953A5 (https=) | ||
| JP2021520208A5 (https=) | ||
| JP7245358B2 (ja) | 抗ｃｄ２５抗体及びその適用 | |
| WO2006020266A2 (en) | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof | |
| NZ601858A (en) | Methods and compositions for diagnosis and treatment of amyloidosis | |
| JP2021517152A5 (https=) | ||
| JP2009509538A5 (https=) | ||
| WO2013017562A1 (en) | Use of the antibody i-3859 for the detection and diagnosis of cancer | |
| EP3397965A1 (en) | Compositions and methods for assessing the risk of cancer occurrence | |
| US12091457B2 (en) | Use for preventing and treating myeloid-derived suppressor cell-related diseases | |
| JP2024509501A5 (https=) | ||
| JP2020515286A5 (https=) | ||
| US20240117042A1 (en) | Immunohistochemistry methods and kir3dl2-specific reagents | |
| JP2023516705A5 (https=) | ||
| JP2021516989A5 (https=) | ||
| JP7821779B2 (ja) | 抗体を使用した細胞表面ｍｉｃａ及びｍｉｃｂの検出 | |
| KR102688094B1 (ko) | Cobll1 단백질 특이 항체 또는 이의 항원 결합 단편, 및 이의 용도 |